Drug Research
No Rush In Indian Generic Drug Firms To Offer COVID Products
Indian generic drugmakers are delaying more investments in COVID-related drugs after making gains in the last two years, according to certain pharmaceutical industry insiders.
BDR Pharmaceuticals' managing director, Dharmesh Shah, stated that when COVID-19 cases start to decline, his company is...
Drug Research
Genomic Studies Utilize Scale As Clinical Utility Catches Up
An innovative system for monitoring chromosomal fragility and copy number alterations in particularly lethal tumours was described earlier this July by researchers from Cambridge University and the National Cancer Research Center in Madrid. Researchers believe this is the first time...
Drug Research
Novavax COVID-19 Vaccine Is Fourth US Option Now Available
As infections in the U.S. continue to be at high levels, the Food and Drug Administration on 13th July approved a fourth vaccination for COVID-19 prevention, authorising Novavax's coronavirus jab for emergency use in adults. The Maryland-based drugmaker's early results on...
News
Alkem Sees 8-11% Growth For Indian Pharmaceutical Industry
When the epidemic subsides, Alkem Laboratories predicts that inflationary pressures and shifting regulatory standards will be the primary concerns to keep an eye on, and that normal business operations would allow the Indian pharmaceutical industry to resume its 8–11%...
News
Sharp expands its reach to China through partnership with ClinsChain
Sharp, a global leader in contract packaging and clinical supply services, has formed a strategic partnership with China-based ClinsChain to expand its reach and capabilities into the Chinese market.
Sharp will collaborate with ClinsChain - who specialize in providing clinical...
News
Switzerland To Get A $518mn Fill-Finish Plant From Lonza
Lonza, a major CDMO, is to invest $518 million in a new, massive fill-finish manufacturing facility in Stein, Switzerland. According to the firm, the facility will use sustainable construction methods to lower carbon emissions when it is finished in...
News
Pfizer And Touchlight Enter Into A Patent Licence Agreement
Pfizer and another pharmaceutical major, Touchlight, have come to a deal on a significant non-exclusive patent licence. Touchlight is a firm that focuses on enzymatic DNA manufacturing to further enhance genetic therapies.
As a result of the licencing arrangement, Pfizer...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read